Open

Leukemia Treatment Study

In this study, we want to see how well a new drug called Quizartinib works for people with Leukemia who do not have a specific mutation called FLT3-ITD. We want to see if this new drug helps improve the condition.

Age & Gender

18 years ~ 70 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

The study involves questionnaires, urinalysis, blood samples, and bone marrow biopsy.

Incentives

In-person visits:
60

Total length of participation:
Maximum of 52 months

Looking for Specific Volunteers

Able to participate:

You have a new diagnosis of Leukemia
You have a good functioning Kidney
You have adequate functioning blood clotting

Not eligible if:

You had previous Chemotherapy or radiotherapy
You have uncontrolled Cardiovascular disease
You have an active systemic fungal, bacterial, or viral infection
You have active Liver Disease
You have uncontrolled Hypothyroidism

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrails@med.unc.edu
(919) 966-4432

Primary Visit Location

UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Joshua Zeidner
Lineberger Comprehensive Cancer Center

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Leukemia)

IRB Number

24-1672

ClinicalTrials.gov

NCT03723681

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.